Background and Aims Despite the availability of several efficacious smoking cessation treatments, fewer than 25% of
INTRODUCTION
While global reductions in the prevalence of daily cigarette smoking have been observed, the world-wide number of smokers continues to increase as the population grows, resulting in substantial adverse effects on health [1] . Cigarette smoking remains the leading cause of premature death and disease in the United States, yet frontline treatments have yielded 1 year post-treatment quit rates of less than 25% [2] . While several approved smoking cessation medications exist with demonstrated efficacy against placebo [3] [4] [5] [6] , there is considerable heterogeneity in response across treatments that may be due, in part, to the complex effects of nicotine on a smokers' cognition and mood [7] [8] [9] . Combining therapies with different mechanisms of action might improve treatment efficacy by addressing some of these individual differences.
Varenicline is a highly selective partial agonist of the α 4 β 2 nicotine cholinergic receptor (nACHR) that ultimately stimulates dopamine release while preventing full stimulation of the nicotine receptor that ensues with co-administered nicotine [10] . Recent meta-analyses [11, 12] and results from the largest randomized controlled trial (RCT) for smoking cessation conducted to date [13] have shown that varenicline is more effective than all other monotherapies for smoking cessation, including all single nicotine replacement therapies (NRTs) and bupropion, with few exceptions [14] . Bupropion (amfebutamone) is an atypical antidepressant whose mechanism of action is thought to be mediated through both dopaminergic (DA) and noradrenergic (NE) systems. Pre-clinical research suggests that bupropion may also act as a non-competitive nicotine antagonist, possibly reducing the reinforcing properties of nicotine [15] . Recent meta-analyses [11, 16] and results from the same large RCT noted above [13] show that bupropion is more effective than placebo, with effectiveness similar to NRT [11, 13] .
Plausible differences in the mechanisms of action of varenicline and bupropion as well as differences in their intensity of action within the same pathways suggests that their combination could offer broader coverage of the neuronal mechanisms implicated in smoking cessation. Both drugs demonstrated reductions in negative affect, craving and some indices of smoking reinforcement (satisfaction) [17, 18] , with varenicline showing potentially stronger effects for many of these outcomes, including craving [2] . Simultaneously, bupropion may offset the deficits in cognitive and attentional functioning related to smoking cessation [19] . This raises the possibility that additive effects may occur during co-administration of these drugs for smoking cessation. While both varenicline and bupropion monotherapies have established efficacy versus placebo, as noted above, the combination of these mediations may result in unexpected or previously undocumented adverse events (AEs) when compared to placebo. Therefore, we included a placebo group in this trial to account for that possibility.
A recent RCT by Ebbert and colleagues [20] found that a combination of varenicline and bupropion may be more effective than varenicline alone up to 6 months post-treatment. Unexpectedly, a small but significant increase in anxiety and depressive symptoms was also noted in the combination group. Two similar RCTs that randomized pre-treatment nicotine patch non-responders (and a small group of responders in the latest trial) to receive the combination of varenicline and bupropion or varenicline alone reported increased abstinence rates in the combination group up to 6 months among male and highly dependent smokers [21, 22] .
Replication and extension of these findings will clarify the degree to which combined pharmacotherapy results in differential benefit based on individual differences in affect and nicotine withdrawal. We hypothesized that combination treatment would (a) result in higher prolonged abstinence rates at the 12-month follow-up (primary outcome) and secondarily at the end of treatment (EOT) and the 6-month follow-up; and (b) would result in lower levels of withdrawal, including negative affect and craving.
METHOD

Study design
In this study, community smokers were recruited at a hospital-based out-patient clinic in Texas to participate in a double-blind, randomized, parallel-groups smoking cessation clinical trial in which 385 participants were randomized to receive varenicline, varenicline + bupropion or placebo, exposed to 12 weeks of treatment, and followed for 12 months. Figures 1 and 2 show the Consolidated Standards of Reporting Trials (CONSORT) study diagram and time-line, respectively. Participant screening for eligibility used a three-step process: (1) initial telephone screen, (2) inperson group orientation visit and (3) subsequent in-person screening/baseline visit to assess medical and other eligibility criteria and conduct baseline assessments (also see Fig. 2 ). Randomization of 385 participants in a 3 : 1 (active : placebo) ratio resulted in: placebo (n = 56; Placebo), varenicline (n = 166; Var) and varenicline + bupropion (n = 163; Combo). This ratio was used to minimize the number of participants who were not offered active pharmacological treatment while preserving the ability to characterize the AEs in the combination group compared to placebo. Adaptive randomization (minimization) [23] balanced groups on gender, race, history of depression, baseline nicotine dependence and previous treatment with either varenicline or bupropion. Participants were enrolled into the trial by study staff, and group assignment was generated with an algorithm developed and managed by study data managers, whose role was limited to data quality and integrity management. Participants, medical and research staff who interacted with participants and the study investigators were blinded to group assignment.
Procedures
Participants
Paid and unpaid media advertising from May 2010 to July 2013 recruited volunteer smokers from the Houston, Texas metropolitan area. Inclusion criteria included: 25-65 years of age; smoke five or more cigarettes per day (CPD); baseline expired carbon monoxide (CO) level greater than 6 parts per million (p.p.m.); fluent in English; stable residence and a working telephone; and be the only participant in his/her household. Exclusion criteria included: currently taking psychotropic medication; having a current psychiatric disorder, psychiatric hospitalization within the last year; life-time history of a psychotic disorder; scoring moderate or higher on the suicidality scale of the Mini International Neuropsychiatric Interview (MINI) [24] ; being involved in any cessation activities; being pregnant or of childbearing potential without the use of birth control; have an uncontrolled chronic medical illness; or having contraindications for bupropion (e.g. history of seizures) or varenicline (e.g. severe renal impairment). The University of Texas MD Anderson Cancer Center Internal Review Board approved this research and the trial ended when the sample size was reached.
Interventions
Pharmacotherapy
All participants took both types of study medication twice daily: placebo varenicline capsules plus placebo bupropion tablets (Placebo); active varenicline capsules plus placebo bupropion tablets (Var) or both active varenicline capsules and active bupropion tablets (Combo). Pfizer (New York, NY, USA) provided the active and matching placebo varenicline capsules and the Biomedical Research Institute of New Mexico (Albuquerque, NM, USA) provided the active and matching placebo bupropion tablets.
Pharmacotherapy was initiated the day after the first treatment visit (see Fig. 2 ), 7-8 days prior to the quit date, and followed the recommended dosing for a total of 12 weeks for varenicline [i.e. 0.5 mg/day for days 1-3; 0.5 mg twice a day (bid) for days 4-7; and 1 mg bid thereafter] and bupropion (150 mg/day for days 1-3; 150 mg bid thereafter). Dose adjustments by the blinded study physician were permitted in an effort to control AEs throughout the trial. Medication compliance was computed using physical pill count in returned bottles at each visit.
Behavioral counseling
As shown in Fig. 2 , following randomization all smokers received individual behavioral smoking cessation counseling conducted over 13 in-person visits (15 minutes each) and two brief supportive telephone calls (5-10 minutes each) during the 12-week active treatment phase (see on-line supplement for counseling details).
Follow-up
As shown in Fig. 2 , follow-up sessions were conducted at the end of the 12-week treatment and at 6 and 12 months post-quit, and involved abstinence and other assessments as noted below.
Assessments
During the baseline screening phase participants were assessed for basic demographics, health and smoking history, psychiatric disorders (using version 5.0 of the MINI International Neuropsychiatric Interview) [24] and nicotine dependence (using the Fagerström Test for Cigarette Dependence; FTCD) [25] [26] [27] .
At baseline and at each in-person counseling and followup visit, participants completed the Positive and Negative Affect Scale (PANAS) [28] , the Wisconsin Smoking Withdrawal Scale (WSWS) [29] , which included subscales of anger, anxiety, concentration, craving, hunger, sadness and sleep, and the Center for Epidemiologic Studies Depression Scale (CES-D), which has been used to measure depressive symptoms in community samples [30, 31] . Additionally, participants reporting smoking between visits completed the Modified Cigarette Evaluation Questionnaire (mCEQ) [32] . Administration of the Sleep Problems Scale occurred at baseline, and 4, 8 and 12 weeks after treatment onset.
Abstinence data were collected at all contacts using a time-line follow-back (TLFB) procedure [33, 34] and abstinence outcomes conformed to the Society of Research on Nicotine and Tobacco (SRNT) [35] guidelines. Measures included prolonged abstinence, defined as no smoking from the quit date to a future time-point (e.g. EOT, 6 and 12 months post-quit date), with relapse defined as smoking on 7 or more consecutive days or smoking at least one cigarette over 2 consecutive weeks within that same time interval. Seven-day point prevalence abstinence was defined as a self-report of no smoking, not even a puff, in the 7 days prior to the selected time-point of interest. Continuous abstinence (2-week grace) was defined as no smoking, not even a puff from 2 weeks past the quit-date (grace period) to a future time-point. Continuous abstinence (Food and Drug Administration; FDA) was defined similarly as no smoking but beginning with the last 4 weeks of treatment, or week 8 of medication in this trial. In-person reports of abstinence were verified by expired CO < 4 p.p.m. Participants unavailable for assessment were considered non-abstinent.
AE monitoring
AEs were monitored at each contact and were classified and graded using the Common Terminology Criteria for Adverse Events (CTCAE) and Common Toxicity Criteria provided by the National Cancer Institute [36] .
Compensation
Participants received compensation for completing assessments for a maximum possible total of $415 throughout all visits.
Outcome measures
The primary outcome for this study is prolonged abstinence at the 12-month follow-up as a function of treatment, specifically between the two active treatment groups, Var and Combo. Secondary outcomes included prolonged abstinence at EOT and the 6-month follow-up, all other abstinence definitions at all three time-points, as well as nicotine withdrawal, affect, smoking reinforcement/satisfaction and sleep problems.
Statistical analysis
All analyses were conducted using SAS version 9.3 and utilized intention-to-treat (ITT) principles, analyzing outcomes for all participants exposed to any level of treatment, with missing abstinence observations imputed as smoking. Logistic regression was used to evaluate the prolonged abstinence at 12 months (primary outcome) as well as secondary abstinence outcomes, including EOT and 6 months abstinence and all other abstinence definitions at each time-point. The primary contrast of interest compared the Combo and Var groups. Missing abstinence observations were imputed as smoking. Longitudinal analyses of nicotine withdrawal (WSWS), negative and positive affect (PANAS), smoking reinforcement/satisfaction (mCEQ) and sleep problems utilized multi-level linear models. Post-hoc follow-up of main effects and interactions used Tukey's honest significant difference (HSD) test to correct for Type 1 error.
Sample size
At the time of the proposal, there were no extant estimates of the effect of combination treatment relative to varenicline alone. Based on our own preliminary clinical data, we estimated tjhat the abstinence differences between Var and Combo would range from 10 to 18% throughout the follow-ups. We calculated that a sample size of 385 (165 in active medication groups; 55 placebo) would provide 80% power to detect a difference of~14% between Var and Combo at 12 months (primary outcome), assuming a 22-23% 12-month abstinence rate for VAR, based on pivotal trials [10, 37] .
RESULTS
Demographics and baseline characteristics
Demographics are presented in Table 1 Table 2 summarizes treatment compliance for pharmacotherapy. Retention of participants through all 12 weeks of treatment ranged from 80.98 to 67.86%, and did not differ by group. Mean percentage of visits completed was comparable throughout treatments, averaging 78.52%. Compliance with prescribed medication dosages averaged > 90% across groups, with the caveat that a physical pill count as used in this study may overestimate adherence [38] . Importantly, we observed no systematic differences in compliance between groups.
Retention and compliance
Pharmacotherapy
Behavioral counseling
Overall, participants attended an average of 10.8 (SD = 3.6) in-clinic counseling sessions, and completed an average of 1.5 (0.8) telephone visits. No differences were noted between medication groups.
Treatment effects on smoking abstinence
At month 12, Var and Combo failed to demonstrate a difference for prolonged abstinence (primary outcome; see Table 3 ). Secondary outcomes of prolonged abstinence at EOT and 6 months, as well as continuous abstinence (2-week grace), FDA continuous abstinence and 7-day point-prevalence for all time-points, are also presented in Table 3 and, in each case, no differences were noted between Var and Combo. The calculation of Bayes factors (BF) using the approach described by Wagenmakers [39] permitted evaluation of the evidence favoring the alternative hypothesis for each treatment comparison at each time-point for each of the four abstinence measures. As stipulated by this journal's editorial guidelines, a BF < 0.3 in favor of the alternative hypothesis provides adequate evidence of no effect. In the case of all abstinence measures at all time-points, the BF was less than 0.3 for contrasts between the combination and varenicline conditions. To reconcile our findings with the previous bupropion/varenicline medication trials [20] [21] [22] , we conducted additional analyses testing for moderation of the treatment effect on abstinence by gender, baseline nicotine dependence and baseline smoking rate. Neither gender, baseline nicotine dependence nor baseline smoking rate moderated the effects of treatment on abstinence. We also tested the same potential moderators in a comparison that included only the two active treatment groups, as none of the previous studies using the combination therapy used a placebo-only group. In this subanalysis, we found that the effect of treatment (Var versus Combo) on continuous abstinence from a 2-week post-quit grace period to EOT was moderated by level of dependence (FTCD ≥ 6 versus FTCD < 6; P = 0.038). The results showed that Combo treatment was superior to Var only among smokers with FTCD ≥ 6: Combo 35 versus Var 16%; odds ratio (OR) = 2.81, 95% CI = 1.07, 7.92. This pattern was consistent at the later time-points but not statistically reliable, and no treatment differences were observed in less-dependent and lighter smokers. 
Other secondary outcomes
All secondary outcome measures are discussed in detail in the on-line Supporting information (see text and Tables S1-S4) and are summarized below.
PANAS
Treatment group differences existed for negative affect (F (2,4078) = 5.24, P ≤ 0.005), which in Tukey's post-hoc analyses showed that participants in the two active conditions reported lower levels of negative affect relative to placebo but did not differ from each other (see Supporting information, Table S3 ).
WSWS
WSWS-Craving Scale demonstrated a time × treatment interaction (F (2,4077) = 3.93, P ≤ 0.02) characterized by a faster rate of decline for varenicline relative to the other groups (see Supporting information, Table S4 ).
The WSWS subscales for anger (F (2,3617) = 6.60, P ≤ 0.001), anxiety (F (2,3841) = 5.88, P ≤ 0.003) and sadness (F (2,3974) = 7.84, P ≤ 0.0001) demonstrated main effects for treatment (see Supporting information, Table  S1 ). Post-hoc analyses showed that smokers in the Combo group reported less anger and sadness than those in the Var condition, while both groups reported lower anxiety relative to Placebo but did not differ from each other (see Supporting information, Table S3 ). Bayes factor V versus P (6) 10.71 (6) 16.07 (9) 25.00 (14) OR (95% CI): C versus P No significant group differences were noted for the CES-D scales, Sleep Problems Scale or the mCEQ (see Supporting information, Tables S1-S3).
AEs
There was a total of 36 serious AEs (SAEs): 24 in the Combo arm, involving eight people; two in the Placebo arm, involving one person; and 10 in the Var arm, involving four people. All SAEs were rated as unlikely or unrelated to medication, except one in the Var arm, which involved a suicide attempt. This SAE was rated as possibly related, although there were extenuating circumstances surrounding the event (see Supporting information for further details).
Supporting information, Tables S5 and S6 , report rates for AEs within each System Organ Class for which an overall treatment group difference was noted (see Supporting information, Table S5 ; alpha = 0.05 uncorrected for multiple comparison) as well as all individual AEs. Relative to Placebo, Combo smokers showed decreased appetite and increased dry mouth, insomnia, dysgeusia, creatinine and edema, while those in the Var group showed higher levels of abnormal dreams, diarrhea and nausea. Pre-existing medical conditions may have contributed to elevations of creatinine, edema and dysgeusia in the combination group (see Supporting information for further discussion).
Negative binomial regression was used to evaluate rates of AEs as a function of treatment, complier status (i.e. ≥ 80% compliance with all medication-taking) and their interaction. The natural logarithm of number of visits attended functioned as an offset to control for participants' treatment exposure time. In participants receiving Combo, compliers reported a lower rate of AEs than non-compliers [relative risk (RR) = 0.53, 95% CI = 0.34-0.82), while no such differences were noted for those for Var or Placebo. Using a similar approach we found that among the Combo group, compliers reported a lower rate of psychiatric AE than non-compliers (RR = 0.39, 95% CI = 0.22-0.70), while similar differences were not found for Var or Placebo. Analyses of psychiatric AEs, excluding abnormal dreaming and insomnia, failed to find this moderating effect.
DISCUSSION
Contrary to previous studies, we did not find evidence that the combination treatment resulted in higher abstinence rates than varenicline alone. Both active treatments demonstrated superiority to placebo on all measures of continuous and prolonged abstinence at all time-points but did not differ from each other. The results confirm previous varenicline trials in demonstrating its efficacy for smoking cessation compared with placebo [20] . Results for 7-day point prevalence were similar, although less consistent. This is due probably to the volatility of the measure resulting from individuals being abstinent at one timepoint and not in another [35] .
We did not find evidence of any treatment interactions with gender or baseline nicotine dependence, as reported previously [20] [21] [22] , in an analysis that included both active treatments and placebo. However, in a subanalysis using only the two active treatments, we found that among more dependent smokers (FTCD ≥ 6) continuous abstinence at the end of treatment was significantly higher for those on combination treatment versus varenicline alone. Both medication groups reduced general negative affect, anxiety and craving. Although there was some evidence that the combination treatment resulted in lower levels of anger and sadness than varenicline and placebo, which did not differ from each other, the differences were relatively small. No differences were noted for depressive symptomatology (CES-D), sleep or reward (mCEQ).
Combination treatment participants reported more occurrences of decreased appetite, dry mouth, edema, abnormal taste, increased creatinine and insomnia. Additionally, participants in the varenicline group reported more diarrhea, nausea and abnormal dreams. No group differences in psychiatric AEs were noted with the exception of abnormal dreams (higher in Var) and insomnia (higher in Combo), neither of which are unexpected with these medications. Ebbert et al. [20] noted increases in anxiety and depression in the combination group compared to the varenicline group, which we did not find. Finally, treatment non-compliers in the combination group, but not in the varenicline group, reported more general and psychiatric AEs than compliers.
The discrepancy between our results and Ebbert and colleagues [20] , which was most similar to our design, is worthy of comment. A potential limitation is our sample size, which contained 86 and 91 fewer smokers in the combination and varenicline groups, respectively. However, the ORs between the studies were quite dissimilar. For Ebbert et al. [20] , significant differences between the two active treatments were noted for EOT and 6-month continuous abstinence only with ORs of 1.49 (95% CI = 1.05-2.12) and 1.52 (95% CI = 1.04-2.22), respectively. The corresponding figures for this study were 1.18 (95% CI = 0.75-1.86) and 0.96 (95% CI = 0.56-1.64), respectively. An increased sample size would be unlikely to rectify these differences. When our study was proposed there was no published evidence for combination therapy. Our sample size calculations were based on preliminary data from our clinic, from which we estimated a treatment difference of 10-18%, favoring combination. Our actual difference was only 4% at EOT and À1.7% at 6 months for continuous abstinence. Corresponding differences in the Ebbert trial were 9.8 and 9%, respectively. Thus, while our projections were somewhat higher than those observed by Ebbert and colleagues, our actual outcomes were substantially different. Some differences of note between the studies is that our sample was more diverse (38 non-white versus 6.5%), less educated and overall less dependent, although mean CPD was nearly identical.
Taken together, there appears to be little evidence from this trial to recommend combination varenicline and bupropion over varenicline alone as a first-line treatment to all smokers. While we did note in one subgroup analysis superiority of combination therapy for highly dependent smokers (FTCD ≥ 6) at EOT, similar to those of Ebbert et al. [20] , the findings were not reliable over time, nor were we able to replicate the advantage noted for those smoking > 20 CPD in that same study, or for males with FTCD scores ≥ 6 and baseline CPD > 20, noted in other previous studies [21, 22] . Admittedly, these latter two studies involved patch non-responders while ours did not, but in our view the evidence favoring combination therapy even for this small subgroup appears obscure, at best. Further study on this subgroup may be warranted, particularly as combination NRT versus patch monotherapy, as used in those studies, is more effective [40, 41] and likely to become more of a frontline treatment. The lack of overall abstinence differences, the absence of consistent subgroup effects, the potential for higher AEs, which also reduces compliance, and the lack of substantial differences in withdrawal symptoms argue against the use of this combination as a frontline treatment at this time.
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